By Emily Olsen | Published May 7, 2026
Executive Summary: The Path to Profitability
Telehealth giant Amwell has signaled a pivotal shift in its financial trajectory, reporting a narrowed net loss for the first quarter of 2026. Despite a year-over-year decline in total revenue, the company’s leadership expressed "increased confidence" in achieving its long-standing goal of reaching positive cash flow from operations by the fourth quarter of this year. CFO Mark Hirschhorn, speaking during the company’s recent earnings call, emphasized that disciplined cost management and a refined operational focus are the primary engines driving this improved outlook.
While total revenue for the quarter landed at $54.9 million—a contraction of approximately 18% compared to the same period in 2025—the company’s internal metrics suggest a stabilization of its business model. By divesting non-core assets and focusing on a singular, consolidated digital health platform, Amwell is attempting to shed the volatility that has defined its post-pandemic performance.
Chronology: From Expansion to Consolidation
To understand Amwell’s current position, one must look at the strategic evolution the company has undergone over the past 24 months.
- 2023: The company secured a landmark $180 million contract with the Defense Health Agency (DHA), tasked with modernizing and replacing the military’s legacy telehealth infrastructure. This was heralded as a major validator of the company’s enterprise-grade platform.
- 2024: Faced with broader market headwinds and cooling demand for standalone virtual care, Amwell began a structural pivot. The company transitioned its focus away from experimental digital health offerings toward a leaner, more predictable subscription-based model.
- 2025: A year of significant divestiture. Amwell offloaded non-core assets, most notably its virtual psychiatric care business, Avel eCare, to streamline its operations. These divestitures were designed to lower the company’s burn rate and allow the engineering team to focus entirely on its flagship "Converge" platform.
- Q2/Q3 2026 (Projected): The immediate horizon is dominated by the upcoming renewal of the Defense Health Agency contract, a critical milestone for the company’s long-term financial health.
Supporting Data: Analyzing the Financials
The financial data provided in the Q1 report paints a picture of a company in transition. The net loss for the quarter was $10.3 million, a marked improvement over the $18.4 million loss reported in the first quarter of 2025. This reduction in losses suggests that the company’s aggressive cost-cutting measures are taking hold.
Key Financial Metrics:
- Total Revenue: $54.9 million (18% year-over-year decrease).
- Subscription Revenue: $24.9 million (23% year-over-year decrease).
- Operational Performance: Strong visit volumes in urgent care and specialized clinical programs served as the primary offset to lower total revenue.
While subscription revenue saw a decline, management noted that this is largely a function of legacy contracts rolling off. Crucially, the renewal and retention rates for the remaining subscription base exceeded expectations. This "stickiness" is what provides CFO Hirschhorn with the confidence to project positive cash flow by Q4. The company is no longer chasing rapid, high-acquisition-cost growth; it is instead prioritizing high-value, recurring enterprise contracts.
Official Responses and Strategic Commentary
During the earnings call, CEO Dr. Ido Schoenberg characterized the current phase of the company as one of "calculated consolidation."
"We are building a single, cohesive platform where our customers can unify their virtual care and digital health ecosystem," Schoenberg stated. By eliminating the friction of managing multiple, disparate vendors, Amwell aims to become the essential backbone for large-scale health systems and government entities.
Regarding the all-important Defense Health Agency (DHA) contract, both Schoenberg and Hirschhorn were pragmatic. The original deal, which has been central to Amwell’s revenue profile, was extended last summer, though it notably excluded behavioral health deployments due to Department of Defense (DoD) budget constraints.
"The renewal of the base contract is expected to be very straightforward," Hirschhorn noted, placing the timeline for completion between the end of Q2 and early Q3. "Regarding the expansion to include behavioral health services, the decision rests with the customer. We are prepared to scale, but we are awaiting the budgetary green light from the DoD."
Implications: What This Means for the Telehealth Sector
The trajectory of Amwell is indicative of a broader maturation phase in the digital health sector. The "pandemic boom" era, characterized by high growth and massive marketing spend, has been replaced by an era of "operational excellence."
1. The Death of the "Growth at All Costs" Model
Amwell’s decision to divest its psychiatric care business and focus on its core platform mirrors trends seen across the health-tech landscape. Investors are no longer rewarding firms for total user acquisition; they are rewarding firms for sustainable margins. The transition to a single-platform strategy suggests that the future of telehealth is enterprise-led rather than direct-to-consumer.
2. The Power of "Sticky" Enterprise Contracts
The renewal of the Elevance Health contract for another three years is a bellwether for the rest of the industry. Large payers are looking for stability in their digital health partners. Amwell’s ability to secure these long-term commitments, even while total revenue dips, signals that its value proposition as a backend infrastructure provider remains robust.
3. Government Contracting as a Stability Anchor
For digital health firms, government contracts—while notoriously slow and subject to political budget cycles—provide a level of revenue predictability that commercial contracts often lack. However, as seen with the DoD budget restrictions, these contracts come with a unique form of risk. Amwell’s future is tied to its ability to manage these high-stakes relationships without becoming overly dependent on a single revenue stream.
4. The Path to Positive Cash Flow
Achieving positive cash flow in the fourth quarter would be a watershed moment for Amwell. It would validate the company’s pivot and potentially open doors for lower-cost financing or re-entry into growth-oriented investments. Conversely, failure to meet this goal would likely force a deeper round of cost-cutting and potentially lead to further divestitures of peripheral assets.
Conclusion: A Measured Outlook
Amwell is currently threading a needle: it must shrink its expense base while keeping its core enterprise customers satisfied. The Q1 results suggest they are succeeding in this delicate balance. By focusing on visit volumes in high-demand areas like urgent care and doubling down on their core technological infrastructure, they have built a credible roadmap toward profitability.
The next six months will be defined by the DHA contract renewal and the company’s ability to demonstrate that its subscription base is truly resilient. If management can hit their Q4 target, it will mark the end of a difficult period of restructuring and the beginning of a new, more sustainable chapter for the telehealth provider. Investors and industry analysts will be watching closely to see if the "increased confidence" expressed by leadership translates into the hard numbers required to turn the tide.
